Shanghai Shyndec Pharmaceutical Co., Ltd.

XSSC:600420 Rapport sur les actions

Capitalisation boursière : CN¥16.4b

Shanghai Shyndec Pharmaceutical Croissance future

Future contrôle des critères 1/6

Shanghai Shyndec Pharmaceutical is forecast to grow earnings and revenue by 16% and 7.6% per annum respectively. EPS is expected to grow by 16.1% per annum. Return on equity is forecast to be 10.3% in 3 years.

Informations clés

16.0%

Taux de croissance des bénéfices

16.1%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices19.3%
Taux de croissance des recettes7.6%
Rendement futur des capitaux propres10.3%
Couverture par les analystes

Low

Dernière mise à jour15 Oct 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

XSSC:600420 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202613,7051,557N/A2,7842
12/31/202512,8761,377N/A2,4902
12/31/202412,0241,173N/A2,2021
9/30/202411,5011,0822,0362,300N/A
6/30/202411,5851,0652,3322,626N/A
3/31/202411,7768441,8802,162N/A
12/31/202312,0706921,3631,720N/A
9/30/202312,4027652,0222,336N/A
6/30/202313,0177482,1862,500N/A
3/31/202313,1327292,4022,708N/A
12/31/202212,9596282,5482,856N/A
9/30/202212,9543631,9242,273N/A
6/30/202212,7003672,1152,503N/A
3/31/202213,2604251,5361,991N/A
12/31/202113,9455681,1581,680N/A
9/30/202113,9036491,1481,712N/A
6/30/202113,9777489661,524N/A
3/31/202113,1827341,4702,002N/A
12/31/202012,5566491,1821,560N/A
9/30/202012,538713153496N/A
6/30/202012,156611-72371N/A
3/31/202012,328607293685N/A
12/31/201912,1996568661,270N/A
9/30/201911,8607032,4182,839N/A
6/30/201911,7236672,3892,779N/A
3/31/201911,3867171,2701,669N/A
12/31/201811,3217061,2701,669N/A
9/30/201810,4166472,2202,530N/A
6/30/20189,791569N/A2,411N/A
3/31/20189,260530N/A2,565N/A
12/31/20178,518516N/A2,315N/A
9/30/20179,086539N/A1,050N/A
6/30/20179,124544N/A869N/A
3/31/20179,324534N/A654N/A
12/31/20169,126477N/A839N/A
9/30/201613,514773N/A1,898N/A
6/30/201612,126697N/A1,821N/A
3/31/201610,388580N/A1,912N/A
12/31/20158,988530N/A1,666N/A
9/30/20152,829206N/A254N/A
6/30/20152,820211N/A50N/A
3/31/20152,882203N/A202N/A
12/31/20142,749190N/A259N/A
9/30/20142,492169N/A292N/A
6/30/20142,442159N/A386N/A
3/31/20142,317137N/A129N/A
12/31/20132,350133N/A207N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 600420's forecast earnings growth (16% per year) is above the savings rate (2.9%).

Bénéfices vs marché: 600420's earnings (16% per year) are forecast to grow slower than the CN market (25.8% per year).

Croissance élevée des bénéfices: 600420's earnings are forecast to grow, but not significantly.

Chiffre d'affaires vs marché: 600420's revenue (7.6% per year) is forecast to grow slower than the CN market (14% per year).

Croissance élevée des revenus: 600420's revenue (7.6% per year) is forecast to grow slower than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: 600420's Return on Equity is forecast to be low in 3 years time (10.3%).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y